Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Skin and oral lesions associated to imatinib mesylate therapy.

Literature DB >> 19037666

Skin and oral lesions associated to imatinib mesylate therapy.

Fernanda Gonçalves Basso¹, Camila Cominato Boer, Maria Elvira Pizzigatti Corrêa, Marcia Torrezan, Maria Letícia Cintra, Marina H C Gallottini de Magalhães, Paulo da Silva Santos, Cármino Antônio de Souza.

Abstract

INTRODUCTION: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. RESULTS AND DISCUSSION: Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 19037666 DOI： 10.1007/s00520-008-0536-8

Source DB: PubMed Journal: Support Care Cancer ISSN： 0941-4355 Impact factor: 3.603

13 in total

1. Cutaneous reactions to STI571.

Authors: M Brouard; J H Saurat
Journal: N Engl J Med Date: 2001-08-23 Impact factor: 91.245

Review 2. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review.

Authors: G Lodi; M Giuliani; A Majorana; A Sardella; C Bez; F Demarosi; A Carrassi
Journal: Br J Dermatol Date: 2004-12 Impact factor: 9.302

Skin and oral lesions associated to imatinib mesylate therapy.

1. Cutaneous reactions to STI571.

Review 2. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review.

3. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.

Review 4. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia.

5. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.

6. Prevalence of oral lichen planus in Brazilian patients with HCV infection.

7. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

8. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

9. Oral lichenoid reaction to imatinib (STI 571, Gleevec).

10. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.

Review 1. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Review 2. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

3. Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).

4. Generalized lichenoid drug eruption associated with imatinib mesylate therapy.